RNA contact with tau protein spurs neurofibrillary tangles in the brain — a defining hallmark of Alzheimer’s and other diseases.
A variety of resources and enjoyable activities are offered for people with memory loss, their caregivers and families.
Most Alzheimer’s drugs in development target beta-amyloid, but targeting another protein, called tau, may be needed.
Patients in need of cataract surgery also see their risk for developing dementia drop by 30% after undergoing the operation, according to new research published today in JAMA Internal Medicine.
Results reported in JAMA Internal Medicine associate cataract surgery with 30% lower risk of dementia in aging population.
Researchers examine links to cognitive decline of hearing loss, military service, and timeliness of diagnosis.
The University of Washington, Kaiser Permanente, and UC San Diego will jointly lead the next phase of an aging-brain study.
UW Medicine was one of the clinical trial sites for aducanumab, a drug approved yesterday by the Food and Drug Administration to slow the progression of Alzheimer’s disease in people with mild symptoms.
Second round of funding focuses on technology-driven solutions to relieve burdens of cognitive aging, trauma and addiction.
Research program analyzes cerebrospinal fluid molecules to seek diagnostic and progression markers as well as treatment targets.